The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State
- PMID: 35799210
- PMCID: PMC9261214
- DOI: 10.1186/s13722-022-00315-4
The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State
Abstract
Background: Opioid use disorder (OUD) is a serious health condition that is effectively treated with buprenorphine. However, only a minority of people with OUD are able to access buprenorphine. Many access points for buprenorphine have high barriers for initiation and retention. Health care and drug treatment systems have not been able to provide services to all-let alone the majority-who need it, and many with OUD report extreme challenges starting and staying on buprenorphine in those care settings. We describe the design and protocol for a study of a rapid access buprenorphine program model in six Washington State communities at existing sites serving people who are unhoused and/or using syringe services programs. This study aimed to test the effectiveness of a Community-Based Medication-First Program model.
Methods: We are conducting a hybrid effectiveness-implementation study of a rapid access buprenorphine model of care staffed by prescribers, nurse care managers, and care navigators. The Community-Based Medication-First model of care was designed as a 6-month, induction-stabilization-transition model to be delivered between 2019 and 2022. Effectiveness outcomes will be tested by comparing the intervention group with a comparison group derived from state records of people who had OUD. Construction of the comparison group will align characteristics such as geography, demographics, historical rates of arrests, OUD medication, and health care utilization, using restriction and propensity score techniques. Outcomes will include arrests, emergency and inpatient health care utilization, and mortality rates. Descriptive statistics for buprenorphine utilization patterns during the intervention period will be documented with the prescription drug monitoring program.
Discussion: Results of this study will help determine the effectiveness of the intervention. Given the serious population-level and individual-level impacts of OUD, it is essential that services be readily available to all people with OUD, including those who cannot readily access care due to their circumstances, capacity, preferences, and related systems barriers.
Keywords: Implementation; Medications for opioid use disorder; Opioid use disorder; Overdose; Protocol.
© 2022. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Similar articles
-
The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.J Subst Abuse Treat. 2020 Jan;108:33-39. doi: 10.1016/j.jsat.2019.07.007. Epub 2019 Jul 19. J Subst Abuse Treat. 2020. PMID: 31358328 Free PMC article.
-
Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: protocol for a hybrid type III effectiveness-implementation study (Project ED HEALTH).Implement Sci. 2019 May 7;14(1):48. doi: 10.1186/s13012-019-0891-5. Implement Sci. 2019. PMID: 31064390 Free PMC article.
-
Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.Implement Sci. 2017 Nov 15;12(1):135. doi: 10.1186/s13012-017-0665-x. Implement Sci. 2017. PMID: 29141653 Free PMC article. Clinical Trial.
-
Medications for management of opioid use disorder.Am J Health Syst Pharm. 2019 Jul 18;76(15):1097-1103. doi: 10.1093/ajhp/zxz105. Am J Health Syst Pharm. 2019. PMID: 31361869 Review.
-
Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review.J Gen Intern Med. 2020 Dec;35(Suppl 3):954-963. doi: 10.1007/s11606-020-06257-4. Epub 2020 Nov 3. J Gen Intern Med. 2020. PMID: 33145687 Free PMC article. Review.
Cited by
-
Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder.JAMA Health Forum. 2023 Oct 6;4(10):e233549. doi: 10.1001/jamahealthforum.2023.3549. JAMA Health Forum. 2023. PMID: 37862034 Free PMC article.
-
County-level neonatal opioid withdrawal syndrome rates and real-world access to buprenorphine during pregnancy: An audit ("secret shopper") study in Missouri.Drug Alcohol Depend Rep. 2024 Feb 2;10:100218. doi: 10.1016/j.dadr.2024.100218. eCollection 2024 Mar. Drug Alcohol Depend Rep. 2024. PMID: 38380272 Free PMC article.
-
Drop-In Wound Care: Calgary's Wound Care Model Centred Around People Experiencing Homelessness.Int Wound J. 2025 Apr;22(4):e70179. doi: 10.1111/iwj.70179. Int Wound J. 2025. PMID: 40159435 Free PMC article.
-
Community-Based Medications First for Opioid Use Disorder - Care Utilization and Mortality Outcomes.Subst Abuse Rehabil. 2024 Sep 14;15:173-183. doi: 10.2147/SAR.S475807. eCollection 2024. Subst Abuse Rehabil. 2024. PMID: 39295965 Free PMC article.
-
Community-Based Wound Care Programs for Unhoused Individuals.J Epidemiol Glob Health. 2023 Dec;13(4):604-614. doi: 10.1007/s44197-023-00157-6. Epub 2023 Oct 17. J Epidemiol Glob Health. 2023. PMID: 37847465 Free PMC article. Review.
References
-
- National Survey on Drug Use and Health . 2018 NSDUH Annual National Report. Vihar: CBHSQ; 2019.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical